Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Conatus Pharmaceuticals Inc.
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01937130CT.gov Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Alcoholic Hepatitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Emricasan (this asset) | Conatus Pharmaceuticals Inc. | P2 | CCC · 53 |
| Acetylcysteine | Centre Hospitalier Universitaire, Amiens | P3 | BB |
| mg-1 | PharmaKing | P2 | B |
| Metadoxine | PharmaKing | P2 | B |
| Selonsertib | Gilead Sciences | P2 | B |
| MG-2 | PharmaKing | P2 | B |
| Pegfilgrastim | Timothy Morgan, MD | P2 | B |
| Prednisolone | Gilead Sciences | P2 | B |
| Resatorvid | Yaqrit Ltd | P2 | CCC |
+3 more in the Alcoholic Hepatitis cohort
Other indications for Emricasan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Dysfunction-Associated Steatohepatitis | — | P2 | B · 61 |
| Portal Hypertension | — | P2 | B · 57 |
| Cirrhosis Of Liver | — | P2 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Emricasan in Alcoholic Hepatitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/emricasan-alcoholic-hepatitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →